Accession Number : ADA309891

Title :   Clinical Trials of Safety and Efficacy of Oral WR 6026 in Treatment of Visceral Leishmaniasis.

Descriptive Note : Final rept. 1 Sep 91-30 Sep 92,

Corporate Author : KENYA MEDICAL RESEARCH INST NAIROBI

Personal Author(s) : Were, J. B.

PDF Url : ADA309891

Report Date : 31 OCT 1992

Pagination or Media Count : 15

Abstract : Under this Cooperative Agreement, the efficacy of an oral 8-aminoquinoline (8.((6-(diethylamino)hexyl)amino)-6-methoxy-4-methylquinoline)(WR6O26) in the treatment of 16 patients with kala azar was evaluated. The first 8 patients received therapy for 2 weeks at a dosage of 0.75-1.00 mg/(kg.day); 1 patient was cured, and in the other 7, a 1-logarithm decrease in the number of splenic parasites and clinical improvement were noted. The next 8 patients received therapy for 4 weeks at the same daily dosage (1 mgl(kg.day)); 4 were cured, and of the other 4 patients, 1- to 2-log decreases in the number of parasites and clinical improvement were noted. The therapy was associated with minimal toxicity; adverse effects included gastrointestinal distress, headache, and methemoglobinemia. The fact that one-half of the patients were cured indicates that future trials with longer regimens and higher dosages are warranted and should include patients for whom existing treatment methods have failed.

Descriptors :   *TOXICITY, *PARASITES, *MEDICAL SERVICES, *LEISHMANIASIS, *ORAL DISEASES, CLINICAL MEDICINE, SAFETY, ADVERSE CONDITIONS, DOSAGE, INFECTIOUS DISEASES, AFRICA, DAILY OCCURRENCE, LANGUAGE TRANSLATION, BLOOD DISEASES, METHEMOGLOBIN, PHARMACOLOGY, ORAL DOSAGE, SPLEEN, ORGANS(ANATOMY), GASTROINTESTINAL SYSTEM, HEADACHES.

Subject Categories : Medicine and Medical Research
      Microbiology

Distribution Statement : APPROVED FOR PUBLIC RELEASE